Stay updated on Phase II Study AFM13 in R/R CD30+ T-cell Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Phase II Study AFM13 in R/R CD30+ T-cell Lymphoma Clinical Trial page.

Latest updates to the Phase II Study AFM13 in R/R CD30+ T-cell Lymphoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded Revision: v3.4.2 and removed Revision: v3.4.1; changes are limited to site version metadata and the removal of a non-critical government-funding maintenance notice. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check21 days agoChange DetectedA site-wide notice regarding government funding was added. The page revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.3%

- Check28 days agoChange DetectedAdded Show glossary and new labels 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data'; capitalization changes were applied to related text; and the site revision was updated from v3.3.4 to v3.4.0.SummaryDifference0.1%

- Check42 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; no visible changes to study details, documents, or page functionality are observed.SummaryDifference0.0%

- Check63 days agoChange DetectedLocations now lists multiple state sites (Alabama, California, Georgia, Louisiana, Michigan, Minnesota, New York, Pennsylvania, Texas, Washington) with an updated Revision: v3.3.3. The HHS Vulnerability Disclosure link was removed.SummaryDifference0.8%

- Check91 days agoChange DetectedRevision: v3.3.2 was added and v3.2.0 was removed.SummaryDifference0.0%

Stay in the know with updates to Phase II Study AFM13 in R/R CD30+ T-cell Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase II Study AFM13 in R/R CD30+ T-cell Lymphoma Clinical Trial page.